According to AI News, Analytical BioSciences Limited (referred to as "BioSciences") and its subsidiary Shanghai Xingsai Biotechnology Co., Ltd. recently announced the signing of an asset purchase agreement with Gilead Sciences Inc. This agreement involves a new method pioneered by Baiao Zhihui in cancer immunotherapy, which induces the formation of tertiary lymphoid structures (TLS) by reprogramming cancer associated fibroblasts (CAFs) in the tumor microenvironment.